Processes For Delivery Of Viscous Drug Therapies
20170312434 ยท 2017-11-02
Inventors
- Eric C. Scribben (Springfield, OH, US)
- Steven M. Risser (Reynoldsburg, OH)
- Amy M. Heintz (Dublin, OH)
- Jeffrey L. Ellis (Gahanna, OH)
- John D. Clay (Gahanna, OH, US)
- Timothy M. Blum (Columbus, OH)
Cpc classification
A61M5/3134
HUMAN NECESSITIES
A61M2205/0238
HUMAN NECESSITIES
A61M5/2448
HUMAN NECESSITIES
A61M2005/3128
HUMAN NECESSITIES
A61M5/204
HUMAN NECESSITIES
A61M5/284
HUMAN NECESSITIES
A61M2005/31598
HUMAN NECESSITIES
A61M5/31596
HUMAN NECESSITIES
A61M5/19
HUMAN NECESSITIES
A61M5/2459
HUMAN NECESSITIES
A61M5/286
HUMAN NECESSITIES
A61M2005/247
HUMAN NECESSITIES
International classification
A61M5/20
HUMAN NECESSITIES
A61M5/28
HUMAN NECESSITIES
Abstract
Core annular flow is used to enable the subcutaneous delivery of a viscous fluid such as a protein therapeutic formulation. The high-viscosity fluid is surrounded by a low-viscosity fluid, and the low-viscosity fluid lubricates the passage of the high-viscosity fluid. This allows the use of protein formulations that have a higher concentration and a higher viscosity at comparatively reduced injection forces and reduced injection times. Several different embodiments of injection devices that provide core annular flow are described herein.
Claims
1. An injection device for delivering a high-viscosity fluid to a patient, comprising: a barrel having an interior space formed by a sidewall for containing at least a high-viscosity fluid to be dispensed by the injection device, a plunger end, and an open end, the open end including a nozzle having a constriction point and an orifice; wherein the interior space of the barrel includes an inner concentric wall positioned within the sidewall, wherein the inner concentric wall defines an inner compartment having the high-viscosity fluid and an outer compartment having a low-viscosity fluid within the barrel, and wherein the inner concentric wall has one or more openings permitting fluid communication between the compartments; a plunger movably operable within at least one compartment of the barrel; wherein the plunger is adapted to provide a depressing force substantially concurrently to the high-viscosity fluid within the inner compartment and the low-viscosity fluid within the outer compartment, thereby producing an annulus of the low-viscosity fluid around a core of the high-viscosity fluid as the fluids are dispensed from the orifice.
2. The injection device of claim 1, wherein a ratio of the viscosity of the high-viscosity fluid to the viscosity of the low-viscosity fluid is from about 60 to about 200.
3. The injection device of claim 1, wherein the ratio of a cross-sectional area of the inner compartment to a cross-sectional area of the outer compartment is from about 2:1 to about 9:1.
4. The injection device of claim 1, wherein the nozzle tapers from the constriction point to the orifice.
5. The injection device of claim 1, further comprising a means for sealing located at the constriction point which ruptures when the plunger is depressed.
6. The injection device of claim 5, wherein the means for sealing is located across only the inner concentric wall.
7. The injection device of claim 1, wherein a valve mechanism is located at the bottom edge of the inner concentric wall.
8. The injection device of claim 1, wherein the inner concentric wall includes a lower wall that tapers to form an aperture, and a means for sealing is located at the aperture.
9. The injection device of claim 1, further comprising a wire extending longitudinally at the aperture.
10. The injection device of claim 1, further comprising grooves at the open end of the barrel to promote core annular flow.
11. An injection device for delivering a high-viscosity fluid to a patient, comprising: a barrel having an interior space formed from a sidewall, an open end, and a closed plunger end, the open end having an orifice; the barrel having a rupturable sealing membrane that separates the interior space of the barrel into an upper compartment and a lower compartment; wherein the upper compartment contains the high-viscosity fluid; wherein an expandable pouch is present in the lower compartment, the pouch having a bottom that splits open upon application of a pressure beyond a threshold value, and a low-viscosity fluid being located in the expandable pouch; and a plunger movably operable within the barrel; wherein depressing the plunger produces a pressure which ruptures the sealing membrane and produces an annulus of the low-viscosity fluid around a core of the high-viscosity fluid as the fluids are dispensed from the orifice.
12. The injection device of claim 11, further comprising grooves at the open end of the barrel to promote core annular flow.
13. An injection device for delivering a high-viscosity fluid to a patient, comprising: a barrel having an interior space formed from a sidewall, an open end, and a closed plunger end, the open end having an orifice; the barrel having a radial wall that separates the interior space of the barrel into an upper compartment and a lower compartment, wherein the floor includes an aperture aligned with the orifice, the aperture being sealed with a sealing means; wherein the upper compartment contains the high-viscosity fluid and the lower compartment contains a low-viscosity fluid; and a plunger movably operable within the barrel; wherein depressing the plunger produces a pressure which pushes the high-viscosity fluid through the aperture and produces an annulus of the low-viscosity fluid around a core of the high-viscosity fluid as the fluids are dispensed from the orifice.
14. The injection device of claim 13, further comprising grooves at the open end of the barrel to promote core annular flow.
15. An injection device for delivering a high-viscosity fluid to a patient, comprising: a barrel having an interior space formed from a sidewall, an open end, and a closed plunger end, the open end having an orifice; and wherein the interior space of the barrel contains one or more beads, wherein each bead includes a core and a shell, the high-viscosity fluid being located in the core; and a plunger movably operable within the barrel; wherein depressing the plunger produces an annulus of a low-viscosity fluid around a core of the high-viscosity fluid as the fluids are dispensed from the orifice.
16. The injection device of claim 15, wherein the interior space of the barrel further comprises the low-viscosity fluid, wherein the shell is a biocompatible polymer which is insoluble in the low-viscosity fluid, and wherein the injection device further includes a means for breaking the shell.
17. The injection device of claim 15, wherein the shell is soluble in the low-viscosity fluid.
18. The injection device of claim 15, wherein the injection device further comprises an inlet at the open end and a fluid reservoir connected to the interior space of the barrel through the inlet, the low-viscosity fluid being located within the fluid reservoir; wherein the bead is shaped to create an annulus within the barrel; and wherein withdrawing the plunger from the barrel causes the low-viscosity fluid to enter the interior space of the barrel.
19. The injection device of claim 18, further comprising a sealing means within the inlet.
20. The injection device of claim 18, further comprising an outlet at the closed plunger end and an outlet reservoir connected to the barrel through the outlet, wherein excess low-viscosity fluid enters the outlet reservoir as the plunger is withdrawn beyond the outlet.
21. The injection device of claim 18, wherein the injection device is stored with the plunger partially depressed into the barrel.
22. The injection device of claim 15, further comprising a sonic generator located at the open end of the barrel for promoting core annular flow.
23. The injection device of claim 15, further comprising grooves at the open end of the barrel for promoting core annular flow.
24. An injection device for delivering a high-viscosity fluid to a patient, comprising: a barrel having an interior space formed from a sidewall, an open end, and a closed plunger end, the interior space containing a low-viscosity fluid and a high-viscosity fluid, and the open end having an orifice; a plunger movably operable within the barrel; and a sonic generator located at the open end of the barrel for producing an annulus of the low-viscosity fluid around a core of the high-viscosity fluid as the fluids are dispensed from the orifice.
25. The injection device of claim 29, further comprising grooves at the open end of the barrel.
26. An injection device for delivering a high-viscosity fluid, comprising: a barrel having an interior space formed from a sidewall, an open end, and a closed plunger end, the interior space containing a low-viscosity fluid and a high-viscosity fluid, and the open end having an orifice and grooves; and a plunger movably operable within the barrel; wherein depressing the plunger produces an annulus of the low-viscosity fluid around a core of the high-viscosity fluid as the fluids are dispensed from the open end.
27. The injection device of claim 31, wherein the sidewall tapers at the open end to an orifice.
28. The injection device of claim 31, further comprising an inner wall within the barrel that separates the barrel into a first compartment and a second compartment.
29. The injection device of claim 33, further comprising a sealing means at a bottom edge of the inner wall.
30. An injection device for creating core annular flow, comprising: a barrel having an interior space formed from a sidewall, an open end having an orifice, and an inner concentric wall within the sidewall, wherein the inner concentric wall divides the interior space into an inner compartment and an outer compartment; a flow diverter located between the inner compartment and the orifice; and a plunger operating within the barrel; wherein the flow diverter is adapted so that depressing the plunger causes fluid in the inner compartment to form an annulus and causes fluid in the outer compartment to flow as a core surrounded by the annulus.
31. The injection device of claim 30, wherein the flow diverter is formed from a flow cap and a flow base; wherein a center of the flow cap connects to the inner concentric wall, and at least one radial spoke extends from the center of the flow cap to an annular ring, an underside of the annular ring including a circumferential groove, the circumferential groove creating an inner ring wall and an outer ring wall; wherein the flow base includes a central surface with at least one radial spoke extending from the central surface to an annular wall; wherein the at least one radial spoke of the flow cap and the at least one radial spoke of the flow base cooperate to form a tunnel that channels fluid from the inner compartment to the circumferential groove.
32. The injection device of claim 31, wherein the central surface of the flow base has a diameter equal to an outer diameter of the inner concentric wall.
33. The injection device of claim 31, wherein the annular wall of the flow base has an outer diameter equal to the outer diameter of the inner ring wall of the flow cap.
34. The injection device of claim 31, wherein the inner concentric wall and the flow cap are formed as one integral component.
35. The injection device of claim 31, wherein the flow cap includes throughbores between the inner concentric wall and the inner ring wall; and wherein the flow base includes throughbores between the central surface and the annular wall.
36. The injection device of claim 31, wherein the flow cap rests upon a horizontal stop surface within a needle hub, and the flow base is seated within the needle hub.
37. The injection device of claim 30, wherein the plunger comprises a central piston located within the inner compartment and a ring piston located within the outer compartment, the central piston and the ring piston being connected to a common shaft.
38. An injection device for creating core annular flow, comprising: a barrel formed by a sidewall and having a lower volume and an upper volume; a core container located within the lower volume, the core container comprising a sidewall and a floor with a central hole; a plunger rod extending through the barrel upper volume and contacting a core plunger in the core container; a needle hub at an end of the barrel opposite the plunger rod, the needle hub having an internal passage and an annular passage; and a hollow pin having at least one side port at an upper tip, the at least one side port being covered by the floor of the core container, the hollow pin regulating flow from the core container to the internal passage of the needle hub; wherein an annular compartment is formed between the sidewall, the core container, the plunger rod, and the needle hub; and wherein high-viscosity fluid can flow from the core container through the hollow pin and the internal passage, and wherein low-viscosity fluid can flow from the annular compartment through the annular passage.
39. The injection device of claim 38, wherein the core plunger and the plunger rod are connected to each other.
40. The injection device of claim 38, wherein the core plunger cooperates with at least one groove at a top of the core container sidewall.
41. The injection device of claim 38, wherein the upper volume of the barrel has a smaller diameter than the lower volume of the barrel.
42. The injection device of claim 38, wherein the core container divides the lower volume into an upper space, a lower space, and a lower annular space fluidly connecting the upper space and the lower space.
43. The injection device of claim 38, wherein the needle hub comprises an internal surface upon which the hollow pin sits, the internal surface having a central hole that communicates with the internal passage and at least one slit spaced apart from the central hole that communicates with the annular passage.
44. The injection device of claim 38, wherein a base of the hollow pin includes a radial flange.
45. The injection device of claim 38, wherein the internal passage and the annular passage of the needle hub are separated by an internal cylindrical wall.
46. An injection device for delivering a high-viscosity fluid to a patient, comprising: a barrel containing the high-viscosity fluid; a needle attached to an orifice in the barrel; and a plunger operating within the barrel; wherein an interior surface of the needle is coated with a low-viscosity fluid such that the high-viscosity fluid does not contact the needle when the plunger is depressed.
47. The injection device of claim 46, wherein the low-viscosity fluid is a phase change material.
48. An injection device for delivering a high-viscosity fluid, comprising: a barrel having an orifice, an interior space that is separated into a first compartment and a second compartment, and at least one channel connecting the second compartment to the first compartment, the channel being shaped so that fluid flows from the second compartment circumferentially against a sidewall of the first compartment to create core annular flow; wherein the first compartment contains the high-viscosity fluid; wherein the second compartment contains a low-viscosity fluid; and a plunger operating within the barrel.
49. The injection device of claim 48, wherein the barrel is an outer barrel containing the first compartment, and further comprising an inner barrel that slides within the outer barrel, the inner barrel containing the second compartment.
50. The injection device of claim 48, wherein the barrel includes an inner wall that divides the interior space of the barrel into the first compartment and the second compartment, the orifice being located within the first compartment.
51-60. (canceled)
61. An injection device for delivering a high-viscosity fluid by core annular flow, wherein upon depressing a plunger, a low-viscosity fluid forms an annulus around a core of the high-viscosity fluid as the fluids are dispensed through an orifice.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0042] The following is a brief description of the drawings, which are presented for the purposes of illustrating the exemplary embodiments disclosed herein and not for the purposes of limiting the same.
[0043]
[0044]
[0045]
[0046]
[0047]
[0048]
[0049]
[0050]
[0051]
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
DETAILED DESCRIPTION
[0084] A more complete understanding of the processes and apparatuses disclosed herein can be obtained by reference to the accompanying drawings. These figures are merely schematic representations based on convenience and the ease of demonstrating the existing art and/or the present development, and are, therefore, not intended to indicate relative size and dimensions of the assemblies or components thereof.
[0085] Although specific terms are used in the following description for the sake of clarity, these terms are intended to refer only to the particular structure of the embodiments selected for illustration in the drawings, and are not intended to define or limit the scope of the disclosure. In the drawings and the following description below, it is to be understood that like numeric designations refer to components of like function. In the following specification and the claims which follow, reference will be made to a number of terms which shall be defined to have the following meanings.
[0086] The singular forms a, an, and the include plural referents unless the context clearly dictates otherwise.
[0087] Numerical values in the specification and claims of this application should be understood to include numerical values which are the same when reduced to the same number of significant figures and numerical values which differ from the stated value by less than the experimental error of conventional measurement technique of the type described in the present application to determine the value.
[0088] All ranges disclosed herein are inclusive of the recited endpoint and independently combinable (for example, the range of from 2 grams to 10 grams is inclusive of the endpoints, 2 grams and 10 grams, and all the intermediate values). The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value; they are sufficiently imprecise to include values approximating these ranges and/or values.
[0089] As used herein, approximating language may be applied to modify any quantitative representation that may vary without resulting in a change in the basic function to which it is related. Accordingly, a value modified by a term or terms, such as about and substantially, may not be limited to the precise value specified, in some cases. In at least some instances, the approximating language may correspond to the precision of an instrument for measuring the value. The modifier about should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression from about 2 to about 4 also discloses the range from 2 to 4.
[0090] The term room temperature refers to a temperature from 23 C. to 25 C.
[0091] Viscosity can be defined in two ways: kinematic viscosity or absolute viscosity. Kinematic viscosity is a measure of the resistive flow of a fluid under an applied force. The SI unit of kinematic viscosity is mm.sup.2/sec, which is 1 centistoke (cSt). Absolute viscosity, sometimes called dynamic or simple viscosity, is the product of kinematic viscosity and fluid density. The SI unit of absolute viscosity is the millipascal-second (mPa-sec) or centipoise (cP), where 1 cP=1 mPa-sec.
[0092] A protein is a sequence of amino acids that is of sufficient chain length to produce a tertiary or quaternary structure. Examples of proteins include monoclonal antibodies, insulin, human growth hormone, and erythropoietin.
[0093] The present disclosure discloses processes for achieving low injection force with high-concentration protein solutions and maintaining the protein stability and activity. The phenomenon of core annular flow (CAF) is used to reduce the pressure required to deliver a given volumetric flow rate. Generally, a highly viscous fluid is delivered in the core of a flow field along with a lower viscosity fluid in an annular region (i.e. between the core and the walls of the delivery system) to lubricate flow and reduce the pressure required relative to non-lubricated flow. The processes of the present disclosure can be used with both manual syringes or auto-injectors and is not limited to cylindrical geometries. For the purposes of this disclosure, the term injection device is used to refer to both manual syringes and auto-injectors of any size or shape.
[0094]
[0095] The barrel 110 is the part of the hypodermic syringe that contains the fluid to be injected into a patient. The barrel 110 is hollow and has a plunger end 112 and a needle end 114. The plunger end may also be referred to as a closed end 112 of the barrel, because fluid will not pass through this end when the plunger 140 is inserted. Similarly, the needle end may also be referred to as an open end 114 of the barrel because fluid can pass through this end when the needle 160 is attached. The barrel is formed from a sidewall 120 that surrounds an interior space 130. The sidewall 120 includes an interior surface 122 and an exterior surface 124. The barrel itself is usually transparent for viewing of fluid within the interior space, and a scale can also be imprinted on the exterior surface. The needle end 114 can be tapered towards an orifice 116 through which fluid exits the interior space 130. The length 132 and width 134 of the barrel is variable, as is its shape, although generally the barrel is cylindrical. In this regard, the diameter of the barrel corresponds to the width 134 when the barrel is cylindrical. The needle end 114 also includes a female fitting 118 to form a leak-free connection with the needle 160. The plunger end 112 also includes a finger flange 115 which flares out from the barrel, and allows the user to press on the plunger 140 with the thumb while holding the barrel in place with two fingers.
[0096] The plunger 140 is used to discharge fluid present in the barrel 110 of the syringe. The plunger 140 includes a shaft 150 with a thumbrest 152 on one end 142 and a stopper or piston 154 on the other end 144. The shaft is long enough for the stopper 154 to travel the length of the interior space 130 of the barrel. The stopper 154 fits snugly against the interior surface 122 of the barrel to make an airtight seal. As previously mentioned, a lubricant (not visible) is typically present between the stopper 154 and the interior surface 122 of the barrel to reduce the gliding force.
[0097] The needle 160 is essentially a small thin tube, and is the part of the syringe that actually pierces the skin of the patient. On one end 162 is a hub 170, which includes a male fitting 172 for attachment to the needle end of the barrel, such as a Luer lock. The other end of the needle 164 is beveled to increase the ease of insertion into the patient.
[0098] In the processes of the present disclosure, core annular flow is used to reduce the pressure needed to dispense a viscous fluid from an injection device.
[0099] It should be noted that the high-viscosity formulation 220 does not contact the sidewall 216 of the barrel. Only the low-viscosity fluid 230 contacts the sidewall 216. In other words, the low-viscosity fluid 230 is between the core 220 (formed by the high-viscosity fluid) and the walls 214 of the barrel. When the plunger is depressed, the low-viscosity fluid lubricates the flow and reduces the pressure required to eject the fluid from the barrel.
[0100] Generally, the low-viscosity annulus and high-viscosity core is produced during flow, and may not always be present within the structure. However, it is possible to create trapped high-viscosity core/low-viscosity annular structures through the use of phase change materials such as ice, thermally sensitive emulsions, etc.
[0101] The contents of the injection device can be arranged to obtain core annular flow by several methods. Some exemplary methods are depicted in the following figures.
[0102] In one method, the high-viscosity fluid and the low-viscosity fluid may be stored in two separate compartments, and then combined when the injection device is depressed. The core annular flow may be generated by directing the flow of the two fluids such that the low-viscosity fluid forms an annulus around the high-viscosity core. This may occur in the needle or within a section of the injection device barrel where the two compartments meet. Again, the injection device barrel need not be cylindrical. If an injection device barrel with an initial compartment containing a square cross section is used, the fluids could be injected on different sides a small distance apart, in order to create the core and annulus once the cylindrical section is reached.
[0103] An example of this method is depicted in
[0104] In use, the plunger 360 is depressed to inject the low-viscosity fluid (not shown) from the interior space 355 of the inner barrel 340 into the interior space 325 of the outer barrel 310 and form an annulus about the high-viscosity fluid located in the outer barrel (indicated by circumferential arrow 305). It is believed that the inner barrel 340 itself should not depress significantly while the plunger 360 is being depressed, because the force required to move the low-viscosity fluid within the inner barrel should be less than the force required to move the high-viscosity fluid within the outer barrel through the needle. Rather, the force of the low-viscosity fluid in a circumferential manner about the sidewall of the outer barrel should eject some of the high-viscosity fluid through the needle until core annular flow is established.
[0105] In another method, the two fluids will naturally adopt a core annular arrangement if they undergo steady flow. When the low-viscosity fluid is injected into a flowing high-viscosity stream, the low-viscosity fluid naturally migrates to the wall to minimize stress (lower energy state) in a process called flow inversion. This results in core annular flow. Such arrangements can be accomplished by taking advantage of non-Newtonian fluid behaviors. For example, the low-viscosity fluid may be a lubricant that has a yield stress that is greater than what can be overcome by buoyancy forces (e.g. density difference between fluids).
[0106]
[0107] In use, it is contemplated that pushing on the plunger 440 will cause both fluids to flow. The low-viscosity fluid is injected through the channel 426 of the inner wall into the high-viscosity fluid, and will naturally migrate against the wall of the needle to create core annular flow.
[0108] In a third method, it is possible to generate core annular flow using a phase change material as the low-viscosity fluid. For example, a thin coating of water is placed on the inside of the barrel or the needle, then captured in place by lowering the temperature to convert the water from its liquid phase into ice. In another section of the injection device, the high-viscosity fluid is captured. This filled injection device would be stored at a temperature below the phase change temperature (in this case, the melting point of the ice). Additives such as salts could be incorporated into the high-viscosity fluid to depress its melting point below that of the water. Upon use, applied heat from the user's hand or an external source would melt the ice, creating an annulus of low-viscosity fluid.
[0109] The core annular flow can be generated in either the injection device barrel, or the needle, or both.
[0110] It is known that suspensions (particles and fluid) will phase separate during flow. The particles will move to the center as the low-viscosity fluid moves to the walls. In the present disclosure, a distinct interface is created between the high-viscosity fluid and the low-viscosity fluid. The two fluids may be miscible, or even composed of the same solvent, but the interface will be present as a distinct boundary between the two fluids. Such a boundary may be defined, for example, by a step change in the concentration of solute in each fluid. The solute is defined as the species responsible for the viscosity, such as a high molecular weight protein. This distinct boundary is in contrast to the continuous concentration gradient that forms due to natural flow-induced phase separation in a suspension.
[0111] It is contemplated that the high-viscosity formulation can be a solution, dispersion, suspension, emulsion, etc. The high-viscosity formulation may contain a protein, such as a monoclonal antibody or some other protein which is therapeutically useful. The protein may have a concentration of from about 150 mg/mL to about 500 mg/mL. The high-viscosity formulation may have an absolute viscosity of from about 5 centipoise to about 1000 centipoise. The high-viscosity formulation may further contain a solvent or non-solvent, such as water, perfluoroalkane solvent, safflower oil, or benzyl benzoate.
[0112] The low-viscosity fluid may be water or an aqueous solution. Alternatively, the low-viscosity fluid may be an organic solvent appropriate for injection, such as a perfluoroalkane solvent, safflower oil, or benzyl benzoate. In embodiments, the low-viscosity fluid has a lower absolute viscosity than the high-viscosity formulation, and has an absolute viscosity of from about 0.3 to about 1000 centipoise.
[0113] The high-viscosity fluid and the low-viscosity fluid may be miscible or immiscible with each other.
[0114] It has been observed that the pressure reduction is proportional to the ratio of the viscosities of the two fluids. Put another way, an increased magnitude in the difference between the viscosities increases the pressure reduction. In some embodiments, the ratio of the viscosity of the high-viscosity formulation to the viscosity of the low-viscosity fluid (i.e. .sub.H/.sub.L) is from 1 to about 100 thousand, including from about 60 to about 200.
[0115] The velocities of the high-viscosity formulation and the low-viscosity fluid are substantially identical at the interface region, as required by physics. Desirably, the velocity gradient of the low-viscosity fluid (i.e. in the annular flow region) is greater than the velocity gradient of the high-viscosity formulation (i.e. in the core flow region). The velocity gradient may be determined theoretically by the equation of motion and rheological properties of the fluids. Velocity gradients can be determined experimentally by visual studies, such as particle image velocimetry of impulse injections of a dyed fluid, or by observation of a pressure drop.
[0116]
[0117] The benefit of the processes of the present disclosure is supported with an analysis considering fully developed annular flow of Newtonian fluids in a cylindrical geometry. The governing equation relating the flow rate to the pressure drop is given by Equation (1):
where Q is the flow rate, PIL is the pressure gradient, is the fraction of the diameter occupied by the core fluid, R is the channel radius, and .sub.1 and .sub.2 are the viscosities of the core and the annular fluids, respectively.
[0118] Results from the analysis are shown in
[0119] As seen in
[0120] The required injection force to inject a protein formulation of a given concentration or viscosity is reduced by the processes of the present disclosure. In embodiments, the high-viscosity pharmaceutical formulation is injected with a force of 20 newtons or less. In embodiments, the high-viscosity pharmaceutical formulation is injected within an injection time of 30 seconds or less.
[0121] The embodiment depicted in
[0122] Another embodiment of an injection device 1000 which is capable of core annular flow is depicted in
[0123] The barrel 1010 is formed from a sidewall 1020 that has an internal diameter 1025. An inner concentric wall 1030 is located within the barrel. An inner compartment 1034 and an outer compartment 1036 within the barrel are defined by the inner concentric wall. In this regard, the inner compartment 1034 has an inner diameter 1031 equal to the internal diameter of the concentric wall. The outer compartment has an annular shape, with a width 1037 that is the difference between the internal diameter 1031 of the sidewall and the external diameter 1033 of the inner concentric wall.
[0124] The open end 1014 of the barrel includes a front wall 1040 that extends from a constriction point 1022 to an orifice 1016. The constriction point is used here to refer to the location on the sidewall 1020 where the barrel begins to reduce from the internal diameter 1025 down to a smaller diameter for fluid to be injected through the orifice 1016. As illustrated here, the constriction point 1022 is the intersection of the sidewall 1020 and the front wall 1040, with the front wall being located in essentially a radial plane (reference numeral 1045). A nipple 1050 is present at the open end 1014 of the barrel to which the needle is attached. The nipple has a smaller diameter 1055 than the barrel 1025.
[0125] The inner concentric wall 1030 includes a bottom edge 1038. An opening 1042 is formed between the inner concentric wall 1030 and the front wall 1040, which permits fluid in the outer compartment 1036 to flow towards the orifice 1016 when the plunger is depressed. Here in
[0126]
[0127] In the embodiments of
[0128] Desirably, the volume ratio of high-viscosity fluid to low-viscosity fluid is as high as possible, since it is the high-viscosity fluid that delivers the desired medication and the low-viscosity fluid essentially serves as a lubricant within the injection device. The radial cross-sectional areas of the inner compartment 1034 and the outer compartment 1036 can be controlled to control the volumetric flow of the two fluids. In this regard, the cross-sectional areas for the two compartments can be determined using the interior diameter of the concentric wall, the internal diameter of the sidewall, and the exterior diameter of the inner concentric wall. In embodiments, the ratio of the cross-sectional area of the inner compartment to the cross-sectional area of the outer compartment is from about 2:1 to about 9:1. In ideal circumstances, the flows of the low-viscosity and high-viscosity fluids meet at the constriction point.
[0129] A means for sealing, such as a sealing membrane, may be used to locate the low-viscosity fluid and the high-viscosity fluid in desired locations prior to the injection device being used (or the plunger being depressed), or to keep the two fluids separated to prevent mixing during storage. In
[0130] In
[0131]
[0132] Two different types of plungers are contemplated. In
[0133] Another variation is shown in
[0134] In another variation, illustrated in
[0135] Another embodiment of an injection device that is capable of core annular flow is illustrated in
[0136]
[0137] In this regard, it is contemplated that the injection device here can be a conventional syringe, as seen in
[0138] Different shells are contemplated for the bead containing the high-viscosity fluid. In some embodiments, the shell is a biocompatible polymer that is insoluble in the low-viscosity fluid. This shell could be cracked or broken by the application of an external force. For example, acoustic cavitation or a laser could be used to penetrate the shell once the bead is within the low-viscosity fluid. Alternatively, the shell could be made from a material that is soluble in the low-viscosity fluid. In such embodiments, it is contemplated that upon dissolution of the shell, the low-viscosity fluid and high-viscosity fluid would be immediately injected into the patient (so that the two fluids do not mix together).
[0139]
[0140] While the barrel already includes openings for the needle (1716) and for the plunger (1712), one additional opening is also present. An inlet 1740 is present at the open end of the injection device and is connected to a fluid reservoir 1742 containing the low-viscosity fluid. In this embodiment, the low-viscosity fluid is stored in the fluid reservoir and the high-viscosity fluid is stored in the form of a bead in the barrel until the injection device is to be used. The injection device 1700 is also stored with the plunger 1760 being partially depressed within the barrel. As illustrated here, the plunger 1760 is a shaft 1762 with a thumbrest 1764 on one end and a piston 1766 at the other end (shown here as resting upon the bead 1730). To prevent flow of the low-viscosity fluid into the barrel, the inlet 1740 may be closed off with a means for closing 1744, such as a sealing membrane (not depicted) or a one-way valve that only permits flow in the direction from the fluid reservoir into the barrel.
[0141] It is contemplated that the injection device is used by first pulling the plunger 1760 out of the barrel 1710. This creates low pressure within the barrel, causing the closing means 1744 to open, i.e. the sealing membrane would be broken or the one-way valve would open. This permits the low-viscosity fluid to enter the barrel and fill the annulus 1736 surrounding the bead of high-viscosity fluid. The low-viscosity fluid rises and surrounds the bead 1730 containing the high-viscosity fluid. The shell 1734 dissolves upon exposure to the low-viscosity fluid, releasing the core of high-viscosity fluid. The plunger 1760 is then depressed (pushed into the barrel), and core annular flow occurs. If the orifice 1716 is sealed off, the pressure will break the seal and permit the fluids to flow into the needle. It is contemplated that the plunger may be shaped so that it cannot entirely depress, leaving some fluid within the injection device. This ensures that any air in the injection device is not injected into the user.
[0142] If desired, an outlet 1750 can be located at the closed end of the injection device, which is connected to an outlet reservoir 1752. It is contemplated that the injection device could be used with beads of different sizes, in which case the needed amount of low-viscosity fluid may vary. If the amount of low-viscosity fluid is too great for the bead that is used, the extra fluid could flow into the outlet reservoir. When present, the fluid reservoir and outlet reservoir can be placed in any orientation around the barrel relative to each other, for example on the same side or on opposite sides. There should be sufficient room left between the finger flange 1715 and the outlet reservoir 1750 to accept the finger of the user.
[0143]
[0144]
[0145] As illustrated in
[0146]
[0147] Regarding
[0148]
[0149] Referring first to
[0150] Referring now to
[0151]
[0152]
[0153] Referring back to
[0154]
[0155] The low-viscosity annular fluid is placed in the inner compartment 2734, while the high-viscosity core fluid is located in the outer compartment 2736.
[0156]
[0157]
[0158] Referring first to
[0159] Referring to
[0160] Referring now to
[0161]
[0162]
[0163]
[0164]
[0165]
[0166] Turning back now to
[0167] Materials for making the various components of the different injection devices disclosed herein are known in the art, as are methods for making such injection devices.
[0168] The processes and devices described herein may be used to deliver as part of the high-viscosity fluid, protein microparticles made using the processes described in U.S. Provisional Patent Application Ser. No. 61/556,047, filed Nov. 4, 2011, the disclosure of which is hereby incorporated by reference in its entirety. They can also be used as part of the systems described in U.S. Provisional Patent Application Ser. No. 61/556,542, filed Nov. 4, 2011, or in the devices described in U.S. Provisional Patent Application Ser. No. 61/556,709, filed Nov. 4, 2011, the disclosures of which are hereby incorporated by reference in their entirety.
[0169] The following examples are for purposes of further illustrating the present disclosure. The examples are merely illustrative and are not intended to limit processes or devices made in accordance with the disclosure to the materials, conditions, or process parameters set forth therein.
Example 1
[0170] Rheological constitutive models describing the relationship between protein concentration and viscosity were constructed to assess the magnitude of concentrations which might be delivered with core annular flow. It was assumed that the maximum allowable forces for an auto-injector and a manual syringe were 10 newtons and 20 newtons, respectively. Two potential low viscosity annular fluids, perfluorohexane (1.1 cP) and perfluorooctyl bromide (0.9 cP), were modeled in the annular region. The maximum concentration of protein in the core region was then calculated for a given viscosity. As a baseline, a lubricant having a viscosity of 10 cP was modeled in the annular region. The results are shown in
Example 2
[0171] Experiments were performed to measure the pressure drop during delivery of a viscous fluid with core annular flow.
[0172] Two high-viscosity fluids were prepared. The first high-viscosity fluid was an aqueous solution of xanthan gum. The xanthan gum was mixed into water at 0.15 weight percent and had an absolute viscosity of 88 cP at 10/s (i.e. 10 Hz). This solution decreased in viscosity with increasing shear rate following a power law curve (n=0.39 and m=357). The core fraction occupied by the xanthan gum during flow experiments was 0.63. The second high-viscosity fluid was an aqueous solution of bovine serum albumin (BSA). BSA was mixed into phosphate buffered saline (PBS) at a concentration of 200 mg/mL and had an absolute viscosity of 10.3 cP at 10/s. This solution decreased in viscosity with increased shear rate following a power law curve (n=0.21 and m=18). The core fraction occupied by the BSA solution during flow experiments was 0.63. The low-viscosity fluid used in the annular region was water.
[0173] The high-viscosity fluids and the water were run through a slit flow apparatus. The apparatus provided a rectangular cross section. The apparatus is depicted in
[0174] The pressure drop was measured with a glass capillary manometer for various flow rates. For comparison, experiments were also performed where only the high-viscosity fluid was run through the slit flow apparatus, i.e. no low-viscosity lubricant was provided.
[0175] The results are shown in
Example 3
[0176] A test stand was made as seen in
[0177]
[0178] Based on this design, a 3 mL plastic Becton-Dickinson (BD) syringe was used for the core fluid syringe. A 1 mL BD syringe was used for the annular fluid syringe. A 5 lbf gas spring with a 2 stroke was used to drive both fluid syringes simultaneously. A latch held the gas spring in the retracted position until a test was run. Two 3-way valves and priming syringes were used to prime both the fluid syringes and the rest of the test cell between runs. At the bottom of the fixture was the test cell which combined the core and annular flows and directed them through a 27 G half-inch-long stainless steel tube and into the fluid catch container.
[0179] Each test run was performed using the following procedure: The gas spring was retracted and the latch was set. Using the 3-way valve and the core priming syringe, the core fluid syringe was filled with 1 mL of core fluid. Using the 3-way valve and the annular priming syringe, the annular fluid syringe was filled with 0.4 mL of annular fluid. Using the 3-way valve and the core priming syringe, the tubing and test cell was primed with core fluid. Using the 3-way valve and the annular priming syringe, the tubing and test cell was primed with annular fluid. Both 3-way valves were set to allow the fluid syringes to open to the test cell and to close off the priming syringes. The latch was then released to initiate the run, pushing the annular fluid and the core fluid with the same force, and the time was recorded to deliver the fluids. Syringes were used for 10 or less consecutive runs with the same fluid, due to friction problems attributed to silicone lubricant on the plunger wearing off.
[0180] Two different fluids were used. The high-viscosity fluid was a glyercol/water solution with a viscosity of 85 centipoise (cP). The low-viscosity fluid was distilled water, with a viscosity of 1 cP. Viscosity was measured using a TA Ar2000ex rheometer, a 0.5 20 mm steel cone, Peltier temperature stabilization, at 23 C. with two minutes equilibration time.
[0181] Four different sets of experiments were run. First, water was used as both the core fluid and the annular fluid. Second, glycerol was used as both the core fluid and the annular fluid. Third, glycerol was used as the core fluid and water was used as the annular fluid. Fourth, to show that the combination of water and glycerol is achieving core annular flow rather than merely reducing the total viscosity by combining, the resultant solution from the third set was used as both the core fluid and the annular fluid. The resultant solution had a viscosity of 17 cP.
[0182] The time was recorded by watching when fluid had completely exited the test cell and entered the catch container. However, when running glycerol for both the core and annular fluids, it was difficult to determine exactly when the fluid had completed delivery. As a result, a note was taken when the plungers of both fluid syringes bottomed out for a conservative estimate.
[0183] The results are shown in Table 1. The two fluids are listed in core/annular.
TABLE-US-00001 TABLE 1 Water/ Glycerol/ Glycerol/ Resultant/ Water Glycerol Water Resultant (sec) (sec) (sec) (sec) Run 1 4 180 6 21 Run 2 3 176 5 23 Run 3 4 188 6 20 Run 4 4 182 6 N/A Run 5 4 174 6 N/A Run 6 4 N/A 8 N/A Run 7 4 N/A N/A N/A Average 4 180 6 21
[0184] The conservative estimate for the glycerol/glycerol run was 85 seconds. The core-annular flow provided a 93% reduction in delivery time when compared to this conservative estimate. In contrast, simply reducing the viscosity of the core fluid by mixing in the volume of annular fluid (i.e. the resultant) resulted in only a 75% reduction in delivery time. While these values depend on the two fluids used and their properties, the test clearly showed that core-annular behavior was occurring and demonstrated a significant increase in performance of the system.
[0185] The present disclosure has been described with reference to exemplary embodiments. Obviously, modifications and alterations will occur to others upon reading and understanding the preceding detailed description. It is intended that the present disclosure be construed as including all such modifications and alterations insofar as they come within the scope of the appended claims or the equivalents thereof.